282 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
BIIB Biogen Inc. $296.86 $62.64B Uptrend
Article Searches
Better Buy: Biogen Inc. vs. Celgene https://www.fool.com/investing/2018/06/03/better-buy-biogen-inc-vs-celgene.aspx?source=iedfolrf0000001 Jun 03, 2018 - Which of these beaten-down biotech stocks wins in a head-to-head match-up?
BIIB: Canaccord Genuity ups to Buy http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20180531095132 May 31, 2018 - Canaccord Genuity issues rating change for BIIB
Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report? http://www.zacks.com/stock/news/304840/why-is-biogen-biib-up-67-since-its-last-earnings-report?cid=CS-ZC-FT-304840 May 24, 2018 - Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Better Buy: Acadia Pharmaceuticals vs. Biogen https://www.fool.com/investing/2018/05/18/better-buy-acadia-pharmaceuticals-vs-biogen.aspx?source=iedfolrf0000001 May 18, 2018 - Which of these beaten-down biotech stocks is in better position to mount a strong comeback?
Should You Invest in the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)? http://www.zacks.com/stock/news/303984/should-you-invest-in-the-powershares-dynamic-biotechnology-genome-portfolio-pbe?cid=CS-ZC-FT-303984 May 17, 2018 - Sector ETF report for PBE
Sangamo Therapeutics Stock History https://www.fool.com/investing/2018/05/17/sangamo-therapeutics-stock-history.aspx?source=iedfolrf0000001 May 17, 2018 - After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.
Better Buy: Amgen Inc. vs. Biogen Inc. https://www.fool.com/investing/2018/05/15/better-buy-amgen-inc-vs-biogen.aspx?source=iedfolrf0000001 May 15, 2018 - Find out which biotech stock stands tallest after a head-to-head matchup.
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents http://www.zacks.com/stock/news/303439/novartis-multiple-sclerosis-drug-gets-fda-nod-for-adolescents?cid=CS-ZC-FT-303439 May 14, 2018 - The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.
Ionis Pharmaceuticals Prepares for Launch https://www.fool.com/investing/2018/05/09/ionis-pharmaceuticals-prepares-for-launch.aspx?source=iedfolrf0000001 May 09, 2018 - The biotech has the potential for two FDA approvals this year.
3 Stocks That Turned $10,000 Into $1 Million https://www.fool.com/investing/2018/05/09/3-stocks-that-turned-10000-into-1-million.aspx?source=iedfolrf0000001 May 09, 2018 - These three biotech stocks delivered monster returns over the past couple of decades. Here's how.

Pages: 123456...29

Page 1>